Irritable Bowel Syndrome

Iterative Scopes, provider of precision medicine technologies for gastroenterology, has entered into a data sharing agreement with Pfizer to accelerate the development of potential new treatments for patients suffering from IBD by standardising endoscopic interpretation.  Context  Currently, disease severity scoring systems, such as the Mayo Endoscopic Score (MES), are used to meet inclusion criteria in IBD […]

4D Pharma, a pharmaceutical company developing Live Biotherapeutic products (LBPs), has announced new faecal microbiome analyses from the completed Phase II trial of Blautix(R) (MRx1234) as a treatment for irritable bowel syndrome with constipation (IBS-C) or with diarrhoea (IBS-D). The new data was presented in an ePoster at Gastro 2021, held from December 9-11, 2021.  The study  The Phase II study was […]

Enbiosis has made breakthrough in the treatment of irritable bowel syndrome (IBS), with 78% of the IBS patients who followed microbiome-based diets seeing symptoms improve dramatically.   Dr. Tarkan Karakan, a gastroenterology specialist who helped conduct the study, said: “We believe this achievement represents a significant step towards demonstrating the efficacy of personalised medical solutions. We examined intestinal flora of IBS […]

4D pharma has released additional positive data from its completed Phase II trial of LBP Blautix in subjects with irritable bowel syndrome with constipation (IBS-C) or with diarrhoea (IBS-D). The data has been presented in a poster session at Digestive Disease Week (DDW), on May 22, 2021, by Professor Eamonn Quigley, Head of Gastroenterology and […]